Brentford, UK–headquartered GSK (LSE/NYSE:GSK) reported long-term data from the phase 3 PRIMA study indicating that the PARP inhibitor Zejula (niraparib) promoted a sustained and clinically meaningful progression-free survival (PFS) benefit in ovarian cancer patients.
The survival benefit was evident across biomarker subgroups, including BRCAm, HRd and HRp.
Patients in the HRd subgroup had a 48% reduction of progression or death compared to placebo.
The estimated probability of no progressive disease or death at four years in the broader population was 24% for niraparib compared to 14% for placebo.
GSK plans to present the updated efficacy analysis data on September 11 at the (European Society for Medical Oncology) ESMO Annual Meeting in Paris.
GSK noted in a news release that the overall survival data are “not yet mature based on the prespecified analysis plan.”
The study tested niraparib as maintenance therapy in first-line ovarian…